Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Show more
Location: 520 Newport Center Drive, Newport Beach, CA, 92660, United States | Website: https://www.evolus.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
443.7M
52 Wk Range
$5.71 - $17.44
Previous Close
$6.86
Open
$6.78
Volume
67,065
Day Range
$6.76 - $7.08
Enterprise Value
496.8M
Cash
61.74M
Avg Qtr Burn
-10.33M
Insider Ownership
11.98%
Institutional Own.
90.37%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Evolysse™ Details Nasolabial fold lines | Approved Quarterly sales | |
Jeuveau (prabotulinumtoxinA-xvfs) Details Glabellar lines , Benign tumor | Approved Quarterly sales | |
Jeuveau “Extra-Strength” Details Glabellar lines | Phase 2 Update |
